Octave® Receives $10 Million Grant from The Michael J. Fox Foundation to Develop and Validate  Biomarker Test for Parkinson’s Disease. Learn More

Octave at CMSC 2023!

Wednesday, May 31 – Saturday, June 3
Aurora, Colorado
Gaylord Rockies Resort & Convention Center

The annual meeting has reached its end, but our mission continues.
Explore Octave’s announcements, presentations and each of the 4 posters presented at this year’s Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting!
Supporter Showcase

Providing Precision Care for MS with Octave’s Solution: Clinical Case Studies & Partner Perspectives

Friday, June 2

The presentation highlighted examples of how Octave’s Multiple Sclerosis Disease Activity (MSDA) Test is being used for making clinical decisions on patients over time, showcased the benefits of the Clinical Insights Program and discussed the quantitative, MS-specific MRI reports.

Key speakers include:

  • Martin I. Belkin, DO, Medical Director at Michigan Institute for Neurological Disorders (MIND) MS Center
  • Audrey Johns, RN, PHN, BSN, MSN, Clinical Nurse Navigator, Multiple Sclerosis Program, Pickup Family Neurosciences Institute – Hoag Hospital
Oral Presentation

Robustness of Emergent MS Phenotypes Derived from Multiprotein Serum Biomarker Data

Thursday, June 1

Our phenoclustering oral presentation at CMSC described how we are using advanced machine learning and statistical techniques at Octave to identify distinct biomarker profiles that deepen MS subtyping and the clinical interpretability of our MSDA test results.

Led by John Foley, MD, Director at Rocky Mountain MS Clinic.

Event Coverage

Analyses of protein levels in blood can help ID MS patient subgroups

MS News Today

Analyses of protein levels in the blood can be used to identify groups of multiple sclerosis (MS) patients with distinct clinical features, new research presented at CMSC from Octave and the Rocky Mountain MS Clinic shows.

Company News

Octave Presents New Data at CMSC Annual Meeting 2023, Adding to Growing Evidence Supporting All Dimensions of its Comprehensive Precision Care Solution for Multiple Sclerosis

Business Wire

New data adds to the growing evidence supporting all dimensions of Octave’s comprehensive Precision Care Solution for MS—MS-specific MRI Insights Program, Clinical Insights Program, and Protein Biomarker Program.